Fig. 6From: Multiscale modeling reveals angiogenesis-induced drug resistance in brain tumors and predicts a synergistic drug combination targeting EGFR and VEGFR pathwaysEffect of the timing of combining VEGFR inhibition. a Combining VEGFRI treatment at 240 h; b Combining VEGFRI treatment at 300 h. The blue and black lines represent the tumor cell survival rates with and without VEGFRI treatment, respectivelyBack to article page